Previous 10 | Next 10 |
CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that two abstracts have been accepted for poster presentations at the Keystone Symposia Precision Genome Engineering meeting, held April 27 to Ma...
Vor Bio (NASDAQ:VOR) said Thursday chief medical officer Christopher Slapak plans to retire. VOR has begun an executive search to replace Slapak. The firm is actively recruiting patients into VBP101, its phase 1/2a first-in-human study of VOR33 in patients with acute myeloid leukemia who are ...
CAMBRIDGE, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Christopher Slapak, Chief Medical Officer for Vor Bio plans to retire. The Vor Bio clinical team is fully resourced and continues to act...
Akron BioProducts, a leading manufacturer of cGMP-compliant technologies for cell and gene therapy, and Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced an agreement to develop and manufacture cGMP nucleases. This collaboration strengthens...
Vor Biopharma (NASDAQ:VOR) has filed for a $350M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for working capital, capital expenditures, and general corporate purposes. The offer...
Vor Biopharma press release (NASDAQ:VOR): Q4 GAAP EPS of -$0.49 beats by $0.08. Cash, equivalents and investments were $207.5 million as of December 31, 2021, which now is anticipated to fund operations into the fourth quarter of 2023. For further details see: Vor Biopharma GAAP EPS of ...
Initial clinical data for Vor Bio’s engineered HSC candidate VOR33 expected in 2H 2022 New program VCAR33 ALLO using healthy donor-derived T cells IND submission expected in 1H 2023 Cash runway extended into Q4 2023 providing additional financi...
CAMBRIDGE, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that Dr. Robert Ang, Vor’s President and Chief Executive Officer, will present virtually at the 11th Annual SVB Leerink Global Health...
Vor Biopharma (VOR +10.3%) is trading higher after the FDA announced it has granted orphan drug designation for a gene-edited product candidate developed by the company for acute myeloid leukemia (AML). The federal agency identified the treatment with the generic name “alloge...
Baird has initiated Vor Biopharma (VOR -2.2%) with a buy rating citing the potential of VOR33 for acute myeloid leukemia ("AML"). The firm has a $38 price target and (193% upside). Analyst Jack Allen said that he expects data on VOR33 due in 1H 2022 will be positive, leading shares higher. Al...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...